Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2016-03-09 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It includes a press release about the company presenting at the 28th Annual ROTH Conference. The document is short (1872 characters) and primarily serves as a regulatory filing to report this event. It does not contain financial statements, detailed financial data, or comprehensive report content. According to the rules, Form 6-K filings are considered Regulatory Filings (RNS) as they are miscellaneous filings that do not fit into other specific categories and often include press releases or event announcements. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-03-09 English
Regulatory Filings 2016
Regulatory Filings
2016-03-08 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a press release about successful final results of a Phase III study, which is typical content for a Form 6-K. The document is short (1913 characters) and does not contain detailed financial statements or comprehensive financial data. It is an interim report type used by foreign private issuers to disclose material information between annual reports. Form 6-K filings are generally classified as Regulatory Filings (RNS) because they serve as miscellaneous regulatory disclosures that do not fit into other specific categories like Annual Report or Interim Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-03-08 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a press release titled 'RedHill Biopharma Provides 2016 R&D Update'. Form 6-K filings are periodic reports submitted by foreign private issuers to provide information that is material to investors but is not an annual report (which would be Form 20-F or 40-F). The document is short (1851 characters) and primarily serves as a regulatory filing to disclose a press release rather than a full financial report or detailed presentation. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2016-03-01 English
FORM F-3
Capital/Financing Update Classification · 100% confidence The document is a Form F-3 Registration Statement filed with the SEC, which is a registration statement used for securities offerings. It includes detailed information about the securities to be offered, the company, risk factors, and other disclosures typical of a prospectus for capital raising. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, confirming it is not merely an announcement or a brief notice.
2016-02-25 English
FORM 20--F
Annual Report FY 2015
2016-02-25 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.